Stanisic, S., A. Cicchetti, C. Porta, G. Procopio, and P. Berto. “Cost-Effectiveness of Cabozantinib in Second-Line Treatment of Metastatic Renal Cell Cancer (mRCC) in Italy”. Global and Regional Health Technology Assessment, vol. 5, no. 1, July 2018, doi:10.33393/grhta.2018.434.